North American Scientific Receives Notice of Compliance from Nasdaq

  
    
  
  
    
      North American Scientific, Inc. (Nasdaq:NASI) today announced that it 
      received a letter from The Nasdaq Stock Market (“Nasdaq”) 
      dated February 4, 2008 providing notice that the Company has 
      demonstrated compliance with Nasdaq Marketplace Rules, and that the 
      Nasdaq Listing Qualifications Panel has determined to continue the 
      listing of the Company’s securities on Nasdaq. 
      In addition, the Nasdaq Staff has approved the Company’s 
      application to list its common stock on The Nasdaq Capital Market. The 
      Company’s common stock will be transferred 
      from The Nasdaq Global Market to The Nasdaq Capital Market effective 
      February 6, 2008 and will continue to trade under the symbol “NASI.”
    
    
      Nasdaq Staff previously notified the Company that the bid price of its 
      shares of common stock had closed at less than $1.00 per share over the 
      previous 30 consecutive business days, and, as a result, it did not 
      comply with Marketplace Rule 4450(a)(5). Therefore, in accordance with 
      Marketplace Rule 4450(e)(2), the Company was provided 180 calendar days, 
      or until April 2, 2008 to regain compliance. Upon transfer to The Nasdaq 
      Capital Market, the Company will be afforded the remainder of this 
      compliance period. The Nasdaq Staff also noted that if compliance with 
      the $1.00 bid price requirement cannot be demonstrated by April 2, 2008, 
      the Company may be afforded an additional compliance period, in 
      accordance with Marketplace Rule 4320(e)(2)(E)(ii).
    
    
      About North American Scientific
    
    
      North American Scientific is a leader in radiation therapy in the fight 
      against cancer. Its innovative products provide physicians with tools 
      for the treatment of various types of cancers. They include Prospera® 
      brachytherapy seeds and SurTRAK™ needles and 
      strands used primarily in the treatment of prostate cancer. In addition, 
      the Company has been gaining clinical experience with its first 
      generation ClearPath™ multi-channel catheter 
      breast brachytherapy devices in 2007, and intends to launch the second 
      generation devices in 2008. They are the only such devices approved for 
      both high dose and continuous release, or low dose, radiation 
      treatments. The devices are designed to provide flexible, precise dose 
      conformance and an innovative delivery system that is intended to offer 
      the more advanced form of brachytherapy for the treatment of breast 
      cancer. Please visit www.nasmedical.com 
      for more information.
    
    
      Statements included in this release that are not historical facts may 
      be considered forward-looking statements that are subject to a variety 
      of risks and uncertainties. There are a number of important factors that 
      could cause actual results to differ materially from those expressed in 
      any forward-looking statements made by the Company including, but not 
      limited to, the impact of competitive products and pricing, 
      technological changes, changes in relationships with strategic partners 
      and dependence upon strategic partners for the performance of critical 
      activities under collaborative agreements, the ability of the Company to 
      successfully directly market and sell its products, uncertainties 
      relating to patent protection and regulatory approval, the stable supply 
      of appropriate isotopes, research and development estimates, market 
      opportunities, risks associated with strategic opportunities or 
      acquisitions the Company may pursue and the risk factors included in the 
      Company’s filings with the Securities and 
      Exchange Commission. Any forward-looking statements contained in this 
      news release speak only as of the date of this release, and the Company 
      undertakes no obligation to revise or update any forward-looking 
      statements, whether as a result of new information, future results or 
      otherwise.